RESUMEN
Asymptomatic and convalescent coronavirus disease 2019 (COVID-19) subjects may carry severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for months in their upper respiratory ways. Desiring to permanently clean the mucosal surfaces, we investigated the chemical agents that fit to rapidly degrade the virus. Among these, hydrogen peroxide, initially tested by two of us for tolerability, showed both good performance and acceptable side effects (burning sensation for 15-20 s). We contacted circles of family physicians and the ATS Milano (Territorial Assistance and Prevention Service), and we tested this procedure on eight persistent carriers of SARS-CoV-2, performing swabs before the procedure and after it until the reappearance of the virus or until 14 days (the incubation period), keeping the surfaces clean with a hypertonic solution. Our patients had a median time from exposure or symptom onset of 111 days, and three had relapsed after being declared "cured" (two consecutive negative swabs after quarantine). One patient had a baseline negative swab and was excluded, and two successfully ended the 14 days' course, four suppressed viral elimination for 72 h, and one for 48 h, all rebounding to weak positive (cycle thresholds above 24). Although temporarily effective, such measures may have some place in the control of viral shedding to protect the most fragile subjects.
Asunto(s)
Tratamiento Farmacológico de COVID-19 , Portador Sano/tratamiento farmacológico , Peróxido de Hidrógeno/uso terapéutico , Oxidantes/uso terapéutico , SARS-CoV-2/efectos de los fármacos , Adulto , Antivirales/uso terapéutico , Portador Sano/virología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Nasofaringe/virología , SARS-CoV-2/aislamiento & purificación , Resultado del Tratamiento , Esparcimiento de Virus/efectos de los fármacosAsunto(s)
Betacoronavirus , Infecciones por Coronavirus/prevención & control , Transmisión de Enfermedad Infecciosa de Paciente a Profesional/prevención & control , Procedimientos Quirúrgicos Oftalmológicos , Pandemias/prevención & control , Neumonía Viral/prevención & control , Procedimientos Quirúrgicos Profilácticos , COVID-19 , Higiene de las Manos , Humanos , Ácido Hipocloroso/uso terapéutico , Control de Infecciones/métodos , Oxidantes/uso terapéutico , Equipo de Protección Personal , Profilaxis Pre-Exposición , SARS-CoV-2RESUMEN
Inflammation is generally accepted as a component of the host defence system and a protective response in the context of infectious diseases. However, altered inflammatory responses can contribute to disease in infected individuals. Many endogenous mediators that drive the resolution of inflammation are now known. Overall, mediators of resolution tend to decrease inflammatory responses and provide normal or greater ability of the host to deal with infection. In the lung, it seems that pro-resolution molecules, or strategies that promote their increase, tend to suppress inflammation and lung injury and facilitate control of bacterial or viral burden. Here, we argue that the demonstrated anti-inflammatory, pro-resolving, anti-thrombogenic and anti-microbial effects of such endogenous mediators of resolution may be useful in the treatment of the late stages of the disease in patients with COVID-19.